Medical condition
Psoriasis
Psoriasis is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- tildrakizumab (ILUMYA) Antineoplastic and immunomodulating agents (L04)
- apremilast (OTEZLA) Antineoplastic and immunomodulating agents (L04)
- dimethyl fumarate (APO-DIMETHYL FUMARATE) Antineoplastic and immunomodulating agents (L04)
- guselkumab (TREMFYA) Antineoplastic and immunomodulating agents (L04)
- ixekizumab (TALTZ) Antineoplastic and immunomodulating agents (L04)
- brodalumab (KYNTHEUM) Antineoplastic and immunomodulating agents (L04)
- deucravacitinib (SOTYKTU) Antineoplastic and immunomodulating agents (L04)
- etanercept (BRENZYS) Antineoplastic and immunomodulating agents (L04)
- methotrexate (ARX-METHOTREXATE) Antineoplastic and immunomodulating agents (L04)
- secukinumab (COSENTYX) Antineoplastic and immunomodulating agents (L04)
- ustekinumab (STELARA) Antineoplastic and immunomodulating agents (L04)
- infliximab (INFLECTRA) Antineoplastic and immunomodulating agents (L04)
Latest Psoriasis news
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Vanda Pharmaceuticals' Imsidolimab Shows Efficacy for Generalized Pustular Psoriasis in NEJM Evidence Study
Vanda Pharmaceuticals announces publication of pivotal Phase III imsidolimab study for generalized pustular psoriasis in NEJM Evidence, supporting BLA submission.
Psoriasis Treatment Pipeline Explodes: 90+ Companies Race to Develop Next-Generation Therapies in 2026
Over 90 pharmaceutical companies are developing innovative psoriasis treatments, with promising therapies like Piclidenoson and Zasocitinib advancing through trials.